Senior insider sale
SVP, Chief Financial Officer at HALOZYME THERAPEUTICS, INC. — senior position signals high conviction
$986.6K
14.70K shares
What this filing means
LABROSSE NICOLE plans to sell 14.70K shares of HALOZYME THERAPEUTICS, INC. valued at approximately $986.6K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 5/15/2026ACC: 0001950047-26-004590
Officer· SVP, Chief Financial Officer
Since Feb 2022
14.70K
Shares to sell
$986.6K
Approx. market value
14.70K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months3
Restricted stock vesting under a registered plan
Services Rendered
2/23/2026
1.36KRestricted stock vesting under a registered plan
Services Rendered
2/20/2026
2.46KRestricted stock vesting under a registered plan
Services Rendered
2/16/2026
10.88KTotal acquired14.70K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/23/2026 | Restricted stock vesting under a registered plan Services Rendered | 1.36K | — |
2/20/2026 | Restricted stock vesting under a registered plan Services Rendered | 2.46K | — |
2/16/2026 | Restricted stock vesting under a registered plan Services Rendered | 10.88K | — |
| Total | 14.70K | ||
Planned & Completed Dispositions1
NASDAQPlanned
Units to sell
14.70K
Market value
$986.6K
5/15/2026
Total
Units
14.70K
Value
$986.6K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
5/15/2026 | 14.70K | $986.6K | NASDAQ | Planned |
| Total | 14.70K | $986.6K | ||